Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
YL-10069 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
YL-10069: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
INCA32459 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
INCA32459: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Super CAR-T(FineImmune Biotechnology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Super CAR-T(FineImmune Biotechnology): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position,
9 min read
Allogeneic adipose-derived mesenchymal stem cells(Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Allogeneic adipose-derived mesenchymal stem cells(Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evid
9 min read
Duvortuxizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Duvortuxizumab: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CD19 CAR-T Expressing IL7 and CCL19(First Affiliated Hospital of Zhejiang University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CD19 CAR-T Expressing IL7 and CCL19(First Affiliated Hospital of Zhejiang University): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical dev
9 min read
Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Pegylated recombinant human endostatin(Simcere Pharmaceutical Group Ltd.): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP
9 min read
BPI-452080 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BPI-452080: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Recombinant oncolytic vaccinia virus(GeneSail Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Recombinant oncolytic vaccinia virus(GeneSail Biotech): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals,
9 min read
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody(Bio-Thera Solutions, Ltd.): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical deve
9 min read
FZ-P001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
FZ-P001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Celyvir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Celyvir: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.